Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT32 | Organism | Mus musculus | Mus musculus | MIC | = | 2.1 | ug/ml | 7097716 |
NPT32 | Organism | Mus musculus | Mus musculus | MIC | = | 19.2 | ug/ml | 7097716 |
NPT1386 | Protein Family | Adrenergic receptor beta | Homo sapiens | Activity | = | -2.58 | 10.1016/S0960-894X(97)00046-2 | |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | IC50 | = | 39 | ug/ml | 2838633 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | IC50 | = | 5.6 | ug/ml | 2838633 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Therapeutic index | = | 7 | 2838633 | |
NPT1747 | Individual Protein | Adenylate cyclase type V | Rattus norvegicus | IC50 | = | 82000 | nM | 14971900 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | TD50 | = | 10 | ug/ml | 2213836 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ED50 | = | 10 | ug/ml | 2213836 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ED50 | = | 16 | ug/ml | 2213836 |
NPT1748 | Organism | African swine fever virus | African swine fever virus | ED50 | = | 40 | ug/ml | 2213836 |
NPT195 | Organism | Vesicular stomatitis virus | Vesicular stomatitis virus | ED50 | > | 10 | ug/ml | 2213836 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ED50 | = | 17.1 | ug/ml | 9216836 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | ED50 | = | 6.6 | ug/ml | 9216836 |
NPT1749 | Organism | Human herpesvirus 3 | Human herpesvirus 3 | ED50 | = | 1.17 | ug/ml | 9216836 |
NPT1750 | Organism | Human herpesvirus 5 | Human herpesvirus 5 | ED50 | = | 6.45 | ug/ml | 9216836 |
NPT1353 | Cell Line | CCRF-HSB-2 | Homo sapiens | IC50 | = | 12.9 | ug/ml | 9216836 |
NPT137 | Cell Line | L1210 | Mus musculus | IC50 | = | 14200 | nM | 10.1016/S0960-894X(97)00044-9 |
NPT2 | Others | Unspecified | IC50 | = | 11900 | nM | 10.1016/S0960-894X(97)00044-9 | |
NPT2 | Others | Unspecified | IC50 | = | 24800 | nM | 10.1016/S0960-894X(97)00044-9 | |
NPT1751 | Individual Protein | Adenosylhomocysteinase | Mus musculus | Ki | = | 30000 | nM | 1995889 |
NPT1753 | Organism | Moloney murine leukemia virus | Moloney murine leukemia virus | IC50 | = | 1 | ug/ml | 1995889 |
NPT168 | Cell Line | P388 | Mus musculus | ID50 | = | 16.8 | nM | 2066996 |
NPT137 | Cell Line | L1210 | Mus musculus | ID50 | = | 21.7 | nM | 2066996 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | ED50 | > | 125 | mg/kg/day | 2329551 |
NPT32 | Organism | Mus musculus | Mus musculus | Survival | = | 10 | % | 6265636 |
NPT32 | Organism | Mus musculus | Mus musculus | Survival | = | 60 | % | 6265636 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 9.8 | ug/ml | 2822928 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | MIC50 | = | 30 | ug/ml | 2822928 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | ID50 | = | 4.8 | ug/ml | 2157013 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | Therapeutic index | = | 5.6 | 2157013 | |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 6.4 | ug/ml | 6092635 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | MIC50 | = | 6.4 | ug/ml | 6092635 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 26.8 | ug/ml | 3033247 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 9.8 | ug/ml | 6298423 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | MIC50 | = | 20.1 | ug/ml | 6298423 |
NPT1756 | Cell Line | PRK | IC50 | = | 7 | ug/ml | 6267280 | |
NPT1756 | Cell Line | PRK | IC50 | = | 3 | ug/ml | 6267280 | |
NPT1756 | Cell Line | PRK | IC50 | = | 10 | ug/ml | 6267280 | |
NPT1756 | Cell Line | PRK | IC50 | = | 0.4 | ug/ml | 6267280 | |
NPT1756 | Cell Line | PRK | IC50 | = | 20 | ug/ml | 6267280 | |
NPT1756 | Cell Line | PRK | IC50 | = | 4 | ug/ml | 6267280 | |
NPT1756 | Cell Line | PRK | IC50 | = | 1 | ug/ml | 6267280 | |
NPT137 | Cell Line | L1210 | Mus musculus | IC50 | = | 14200 | nM | 9871764 |
NPT112 | Cell Line | MOLT-4 | Homo sapiens | IC50 | = | 11900 | nM | 9871764 |
NPT404 | Cell Line | CCRF-CEM | Homo sapiens | IC50 | = | 24800 | nM | 9871764 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ID50 | = | 13.6 | ug/ml | 3411597 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ID50 | = | 2.1 | ug/ml | 3411597 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ID50 | = | 1.9 | ug/ml | 3411597 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | ID50 | = | 49.9 | ug/ml | 3411597 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ID50 | = | 9.8 | ug/ml | 3411597 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 15 | ug/ml | 3035178 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 18 | ug/ml | 3035178 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 34 | ug/ml | 3035178 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 6 | ug/ml | 3035178 |
NPT1757 | Organism | unidentified influenza virus | unidentified influenza virus | MIC50 | = | 56 | ug/ml | 3035178 |
NPT2 | Others | Unspecified | Ratio | = | 0.63 | 3035178 | ||
NPT2 | Others | Unspecified | Ratio | = | 1.3 | 3035178 | ||
NPT2 | Others | Unspecified | Ratio | = | 1.5 | 3035178 | ||
NPT2 | Others | Unspecified | Ratio | = | 0.95 | 3035178 | ||
NPT2 | Others | Unspecified | Ratio | = | 1.44 | 3035178 | ||
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ID50 | = | 0.011 | nM | 2521518 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | ID50 | = | 0.075 | nM | 2521518 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 18 | ug/ml | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 70000 | nM | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 22 | ug/ml | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 80000 | nM | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 15 | ug/ml | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 60000 | nM | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 45 | ug/ml | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 170000 | nM | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 5 | ug/ml | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 20000 | nM | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 24 | ug/ml | 3001308 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC50 | = | 90000 | nM | 3001308 |
NPT1758 | Individual Protein | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Hepatitis C virus | IC50 | = | 50000 | nM | 15084127 |
NPT1758 | Individual Protein | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Hepatitis C virus | EC50 | > | 50000 | nM | 15084127 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC50 | = | 9.5 | ug/ml | 6321734 |
NPT32 | Organism | Mus musculus | Mus musculus | LD50 | > | 750 | mg/kg | 3950905 |
NPT1171 | Cell Line | HEp-2 | Homo sapiens | MIC | = | 10 | ug/ml | 6325694 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ID50 | = | 2 | ug/ml | 2544721 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ID50 | = | 1 | ug/ml | 2544721 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ID50 | = | 1.8 | ug/ml | 2544721 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC | = | 10 | ug/ml | 4067994 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | MIC | = | 10 | ug/ml | 4067994 |
NPT137 | Cell Line | L1210 | Mus musculus | ID50 | = | 21 | ug/ml | 2459384 |
NPT1759 | Cell Line | FM3A | Mus musculus | ID50 | = | 21.1 | ug/ml | 2459384 |
NPT605 | Organism | Homo sapiens | Homo sapiens | ID50 | = | 25.9 | ug/ml | 2459384 |
NPT2 | Others | Unspecified | ID50 | = | 16.7 | ug/ml | 2459384 | |
NPT419 | Organism | Oryctolagus cuniculus | Oryctolagus cuniculus | MIC | = | 20 | ug/ml | 2459384 |
NPT419 | Organism | Oryctolagus cuniculus | Oryctolagus cuniculus | MIC | = | 7 | ug/ml | 2459384 |
NPT419 | Organism | Oryctolagus cuniculus | Oryctolagus cuniculus | MIC | = | 10 | ug/ml | 2459384 |
NPT419 | Organism | Oryctolagus cuniculus | Oryctolagus cuniculus | MIC | = | 2 | ug/ml | 2459384 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | MIC | = | 70 | ug/ml | 2459384 |
NPT165 | Cell Line | HeLa | Homo sapiens | MIC | = | 20 | ug/ml | 2459384 |
NPT605 | Organism | Homo sapiens | Homo sapiens | MIC | = | 7 | ug/ml | 2459384 |
NPT165 | Cell Line | HeLa | Homo sapiens | ID50 | = | 0.046 | nM | 3339608 |
NPT165 | Cell Line | HeLa | Homo sapiens | ID50 | = | 27.7 | nM | 3339608 |
NPT91 | Cell Line | KB | Homo sapiens | ID50 | = | 89.8 | nM | 3339608 |
NPT91 | Cell Line | KB | Homo sapiens | ID50 | = | 25.4 | nM | 3339608 |
NPT168 | Cell Line | P388 | Mus musculus | ID50 | = | 12.7 | nM | 3339608 |
NPT168 | Cell Line | P388 | Mus musculus | ID50 | = | 10.8 | nM | 3339608 |
NPT137 | Cell Line | L1210 | Mus musculus | ID50 | = | 23.6 | nM | 3339608 |
NPT116 | Cell Line | HL-60 | Homo sapiens | IC50 | = | 20.9 | ug/ml | 9371251 |
NPT1761 | Cell Line | Erythroleukemia cell line | ID50 | = | 0.094 | nM | 3862866 | |
NPT1761 | Cell Line | Erythroleukemia cell line | ID50 | = | 0.003 | nM | 3862866 | |
NPT1762 | Organism | Macacine herpesvirus 1 | Macacine herpesvirus 1 | EC50 | = | 28000 | nM | 17438061 |
NPT1762 | Organism | Macacine herpesvirus 1 | Macacine herpesvirus 1 | EC50 | = | 35000 | nM | 17438061 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | EC50 | = | 7000 | nM | 17438061 |
NPT189 | Cell Line | Vero | Chlorocebus aethiops | CC50 | = | 38000 | nM | 17438061 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | EC50 | = | 6200 | nM | 19097789 |
NPT1764 | Organism | Cowpox virus | Cowpox virus | EC50 | = | 12600 | nM | 19097789 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | EC50 | = | 1000 | nM | 19097789 |
NPT1764 | Organism | Cowpox virus | Cowpox virus | EC50 | = | 1400 | nM | 19097789 |
NPT859 | Cell Line | HFF | Homo sapiens | CC50 | > | 100000 | nM | 19097789 |
NPT859 | Cell Line | HFF | Homo sapiens | CC50 | = | 90000 | nM | 19097789 |
NPT1766 | Organism | Human herpesvirus 1 strain KOS | Human herpesvirus 1 strain KOS | EC50 | = | 35000 | nM | 20000418 |
NPT1766 | Organism | Human herpesvirus 1 strain KOS | Human herpesvirus 1 strain KOS | EC50 | = | 42000 | nM | 20000418 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | EC50 | = | 8300 | nM | 20000418 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | EC50 | = | 10000 | nM | 20000418 |
NPT2 | Others | Unspecified | Inhibition | = | 50 | % | 20000418 | |
NPT1592 | Individual Protein | Dipeptidyl peptidase IV | Homo sapiens | IC50 | = | 62 | nM | 20000418 |
NPT1762 | Organism | Macacine herpesvirus 1 | Macacine herpesvirus 1 | EC50 | = | 26500 | nM | 19858259 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | EC50 | = | 26500 | nM | 19858259 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | EC50 | = | 26500 | nM | 19858259 |
NPT1762 | Organism | Macacine herpesvirus 1 | Macacine herpesvirus 1 | EC50 | = | 37800 | nM | 19858259 |
NPT1762 | Organism | Macacine herpesvirus 1 | Macacine herpesvirus 1 | EC50 | = | 46100 | nM | 19858259 |
NPT2 | Others | Unspecified | Inhibition | = | 40 | % | 18026094 | |
NPT1768 | Organism | Vaccinia virus Copenhagen | Vaccinia virus Copenhagen | IC50 | = | 2000 | nM | 21641218 |
NPT7 | Individual Protein | Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus | Potency | 89125.1 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 12589.3 | nM | PubChem BioAssay data set | ||
NPT1019 | Organism | Trichomonas vaginalis | Trichomonas vaginalis | IC50 | = | 3600 | nM | 22579483 |
NPT1019 | Organism | Trichomonas vaginalis | Trichomonas vaginalis | GI | = | 100 | % | 22579483 |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | 7307.8 | nM | PubChem BioAssay data set | |
NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | 1995.3 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 366.3 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 461.1 | nM | PubChem BioAssay data set | ||
NPT73 | Individual Protein | Solute carrier organic anion transporter family member 1B1 | Homo sapiens | Inhibition | = | 103.09 | % | 23571415 |
NPT72 | Individual Protein | Solute carrier organic anion transporter family member 1B3 | Homo sapiens | Inhibition | = | 90.86 | % | 23571415 |
NPT471 | Organism | Trypanosoma brucei brucei | Trypanosoma brucei brucei | IC50 | > | 100000 | nM | 24283924 |
NPT2 | Others | Unspecified | Potency | 28183.8 | nM | PubChem BioAssay data set | ||
NPT168 | Cell Line | P388 | Mus musculus | LD50 | = | 0.0001 | nM | 191615 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC | = | 12 | ug/ml | 195055 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | MIC | = | 12 | ug/ml | 195055 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ID50 | = | 2.6 | nM | 195058 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ID50 | = | 3.7 | nM | 195058 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | ID50 | = | 1.4 | 10'-6M | 195058 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | ID50 | = | 1.5 | nM | 195058 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | MIC | = | 1400 | nM | 202709 |
NPT334 | Organism | Vaccinia virus | Vaccinia virus | MIC | = | 26000 | nM | 202709 |
NPT1766 | Organism | Human herpesvirus 1 strain KOS | Human herpesvirus 1 strain KOS | MIC | = | 14000 | nM | 202709 |
NPT1766 | Organism | Human herpesvirus 1 strain KOS | Human herpesvirus 1 strain KOS | MIC | = | 3500 | nM | 202709 |
NPT2 | Others | Unspecified | Activity | = | 71 | % | 209191 | |
NPT2 | Others | Unspecified | Activity | = | 94 | % | 209191 | |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Activity | = | 100 | % | 722731 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Activity | = | 54 | % | 722731 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Activity | = | 0 | % | 722731 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Activity | = | 63 | % | 722731 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Activity | = | 69 | % | 722731 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | Activity | = | 64 | % | 722731 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC | = | 3.2 | ug/ml | 184282 |
NPT190 | Organism | Human herpesvirus 1 | Human herpesvirus 1 | MIC | = | 12 | ug/ml | 195054 |
NPT1141 | Organism | Human herpesvirus 2 | Human herpesvirus 2 | MIC | = | 12 | ug/ml | 195054 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC21448 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC107374 |
1.0 | High Similarity | NPC156461 |
0.9925 | High Similarity | NPC189068 |
0.9925 | High Similarity | NPC164665 |
0.9851 | High Similarity | NPC219313 |
0.9851 | High Similarity | NPC269827 |
0.9851 | High Similarity | NPC309832 |
0.9848 | High Similarity | NPC229974 |
0.9697 | High Similarity | NPC209525 |
0.9697 | High Similarity | NPC161659 |
0.9565 | High Similarity | NPC211025 |
0.9565 | High Similarity | NPC185991 |
0.9565 | High Similarity | NPC85689 |
0.9552 | High Similarity | NPC314152 |
0.9549 | High Similarity | NPC317821 |
0.9496 | High Similarity | NPC321814 |
0.9496 | High Similarity | NPC472816 |
0.9429 | High Similarity | NPC212551 |
0.9429 | High Similarity | NPC130586 |
0.9429 | High Similarity | NPC302778 |
0.9429 | High Similarity | NPC164952 |
0.9362 | High Similarity | NPC174802 |
0.9348 | High Similarity | NPC121222 |
0.9296 | High Similarity | NPC224076 |
0.9231 | High Similarity | NPC226245 |
0.9231 | High Similarity | NPC316618 |
0.9231 | High Similarity | NPC239737 |
0.922 | High Similarity | NPC207633 |
0.9185 | High Similarity | NPC129756 |
0.9149 | High Similarity | NPC161224 |
0.9078 | High Similarity | NPC150853 |
0.9007 | High Similarity | NPC136349 |
0.8966 | High Similarity | NPC311197 |
0.8966 | High Similarity | NPC54320 |
0.8966 | High Similarity | NPC313754 |
0.8919 | High Similarity | NPC323091 |
0.8897 | High Similarity | NPC52238 |
0.8832 | High Similarity | NPC33996 |
0.8824 | High Similarity | NPC320818 |
0.8819 | High Similarity | NPC328479 |
0.8553 | High Similarity | NPC261595 |
0.8523 | High Similarity | NPC195140 |
0.8497 | Intermediate Similarity | NPC324033 |
0.8497 | Intermediate Similarity | NPC321458 |
0.8462 | Intermediate Similarity | NPC326529 |
0.8456 | Intermediate Similarity | NPC93365 |
0.8408 | Intermediate Similarity | NPC319100 |
0.8408 | Intermediate Similarity | NPC189261 |
0.8408 | Intermediate Similarity | NPC324198 |
0.8366 | Intermediate Similarity | NPC324484 |
0.8323 | Intermediate Similarity | NPC326082 |
0.8323 | Intermediate Similarity | NPC290959 |
0.8312 | Intermediate Similarity | NPC325906 |
0.8286 | Intermediate Similarity | NPC61198 |
0.8214 | Intermediate Similarity | NPC262926 |
0.8067 | Intermediate Similarity | NPC321052 |
0.8042 | Intermediate Similarity | NPC30326 |
0.8014 | Intermediate Similarity | NPC319221 |
0.8 | Intermediate Similarity | NPC313897 |
0.7959 | Intermediate Similarity | NPC274384 |
0.7959 | Intermediate Similarity | NPC89147 |
0.7943 | Intermediate Similarity | NPC324009 |
0.7891 | Intermediate Similarity | NPC251233 |
0.7891 | Intermediate Similarity | NPC211820 |
0.7877 | Intermediate Similarity | NPC186619 |
0.7838 | Intermediate Similarity | NPC177169 |
0.7785 | Intermediate Similarity | NPC64705 |
0.7785 | Intermediate Similarity | NPC232408 |
0.7771 | Intermediate Similarity | NPC24589 |
0.777 | Intermediate Similarity | NPC318590 |
0.7738 | Intermediate Similarity | NPC78941 |
0.7738 | Intermediate Similarity | NPC282458 |
0.7718 | Intermediate Similarity | NPC317746 |
0.7703 | Intermediate Similarity | NPC74306 |
0.7703 | Intermediate Similarity | NPC315642 |
0.7697 | Intermediate Similarity | NPC326694 |
0.7529 | Intermediate Similarity | NPC313514 |
0.7516 | Intermediate Similarity | NPC33382 |
0.7469 | Intermediate Similarity | NPC125659 |
0.7469 | Intermediate Similarity | NPC168702 |
0.7378 | Intermediate Similarity | NPC222174 |
0.7329 | Intermediate Similarity | NPC14590 |
0.7267 | Intermediate Similarity | NPC321393 |
0.7222 | Intermediate Similarity | NPC276373 |
0.7214 | Intermediate Similarity | NPC327579 |
0.7182 | Intermediate Similarity | NPC5802 |
0.7143 | Intermediate Similarity | NPC157821 |
0.7015 | Intermediate Similarity | NPC476564 |
0.698 | Remote Similarity | NPC57279 |
0.6959 | Remote Similarity | NPC104011 |
0.6959 | Remote Similarity | NPC246193 |
0.6917 | Remote Similarity | NPC87981 |
0.6917 | Remote Similarity | NPC174114 |
0.6849 | Remote Similarity | NPC248007 |
0.6804 | Remote Similarity | NPC250178 |
0.6763 | Remote Similarity | NPC312187 |
0.6763 | Remote Similarity | NPC4837 |
0.6644 | Remote Similarity | NPC139776 |
0.6623 | Remote Similarity | NPC287876 |
0.6596 | Remote Similarity | NPC103388 |
0.6567 | Remote Similarity | NPC107160 |
0.6556 | Remote Similarity | NPC14330 |
0.6522 | Remote Similarity | NPC18335 |
0.6471 | Remote Similarity | NPC21461 |
0.6471 | Remote Similarity | NPC160666 |
0.6446 | Remote Similarity | NPC472834 |
0.6377 | Remote Similarity | NPC158055 |
0.6333 | Remote Similarity | NPC109322 |
0.6259 | Remote Similarity | NPC68938 |
0.6164 | Remote Similarity | NPC313547 |
0.6159 | Remote Similarity | NPC5707 |
0.6145 | Remote Similarity | NPC164845 |
0.6135 | Remote Similarity | NPC217656 |
0.6098 | Remote Similarity | NPC89139 |
0.6087 | Remote Similarity | NPC296437 |
0.6078 | Remote Similarity | NPC180493 |
0.6049 | Remote Similarity | NPC470266 |
0.604 | Remote Similarity | NPC189314 |
0.6028 | Remote Similarity | NPC476561 |
0.5988 | Remote Similarity | NPC244700 |
0.5976 | Remote Similarity | NPC476528 |
0.5976 | Remote Similarity | NPC476433 |
0.5939 | Remote Similarity | NPC476520 |
0.5939 | Remote Similarity | NPC476522 |
0.5939 | Remote Similarity | NPC474986 |
0.5939 | Remote Similarity | NPC476013 |
0.593 | Remote Similarity | NPC472833 |
0.5928 | Remote Similarity | NPC476408 |
0.5914 | Remote Similarity | NPC265111 |
0.5904 | Remote Similarity | NPC476521 |
0.5903 | Remote Similarity | NPC119133 |
0.587 | Remote Similarity | NPC473585 |
0.5833 | Remote Similarity | NPC476099 |
0.5829 | Remote Similarity | NPC18308 |
0.5829 | Remote Similarity | NPC472832 |
0.5796 | Remote Similarity | NPC180462 |
0.5775 | Remote Similarity | NPC293163 |
0.5764 | Remote Similarity | NPC59314 |
0.5724 | Remote Similarity | NPC476562 |
0.5697 | Remote Similarity | NPC210947 |
0.5695 | Remote Similarity | NPC63433 |
0.5667 | Remote Similarity | NPC41958 |
0.5667 | Remote Similarity | NPC256849 |
0.5655 | Remote Similarity | NPC10466 |
0.5638 | Remote Similarity | NPC47936 |
0.5621 | Remote Similarity | NPC174020 |
0.561 | Remote Similarity | NPC470140 |
0.5602 | Remote Similarity | NPC470139 |
0.56 | Remote Similarity | NPC60537 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC21448 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD249 | Approved |
1.0 | High Similarity | NPD250 | Approved |
0.9851 | High Similarity | NPD195 | Approved |
0.9851 | High Similarity | NPD186 | Discovery |
0.9565 | High Similarity | NPD283 | Approved |
0.9552 | High Similarity | NPD185 | Approved |
0.9429 | High Similarity | NPD338 | Approved |
0.9429 | High Similarity | NPD3107 | Discontinued |
0.9429 | High Similarity | NPD242 | Approved |
0.9429 | High Similarity | NPD1369 | Phase 2 |
0.9429 | High Similarity | NPD1750 | Clinical (unspecified phase) |
0.9412 | High Similarity | NPD166 | Approved |
0.9403 | High Similarity | NPD193 | Suspended |
0.9362 | High Similarity | NPD339 | Approved |
0.9296 | High Similarity | NPD169 | Phase 2 |
0.9231 | High Similarity | NPD1732 | Phase 3 |
0.9231 | High Similarity | NPD2646 | Discontinued |
0.9231 | High Similarity | NPD2624 | Phase 2 |
0.9007 | High Similarity | NPD548 | Clinical (unspecified phase) |
0.8966 | High Similarity | NPD219 | Phase 3 |
0.8966 | High Similarity | NPD216 | Approved |
0.8966 | High Similarity | NPD218 | Approved |
0.8966 | High Similarity | NPD220 | Clinical (unspecified phase) |
0.8966 | High Similarity | NPD217 | Approved |
0.8759 | High Similarity | NPD213 | Clinical (unspecified phase) |
0.8759 | High Similarity | NPD214 | Approved |
0.8742 | High Similarity | NPD2647 | Phase 3 |
0.8593 | High Similarity | NPD248 | Discontinued |
0.8553 | High Similarity | NPD247 | Clinical (unspecified phase) |
0.8462 | Intermediate Similarity | NPD5666 | Phase 2 |
0.8456 | Intermediate Similarity | NPD546 | Clinical (unspecified phase) |
0.8456 | Intermediate Similarity | NPD9632 | Phase 3 |
0.8431 | Intermediate Similarity | NPD7988 | Suspended |
0.8408 | Intermediate Similarity | NPD4171 | Clinical (unspecified phase) |
0.8354 | Intermediate Similarity | NPD1412 | Clinical (unspecified phase) |
0.8312 | Intermediate Similarity | NPD1776 | Approved |
0.8312 | Intermediate Similarity | NPD1777 | Approved |
0.8309 | Intermediate Similarity | NPD870 | Clinical (unspecified phase) |
0.8286 | Intermediate Similarity | NPD252 | Clinical (unspecified phase) |
0.825 | Intermediate Similarity | NPD4716 | Approved |
0.8235 | Intermediate Similarity | NPD3083 | Approved |
0.8199 | Intermediate Similarity | NPD4744 | Clinical (unspecified phase) |
0.8098 | Intermediate Similarity | NPD1692 | Approved |
0.8056 | Intermediate Similarity | NPD549 | Approved |
0.8052 | Intermediate Similarity | NPD516 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD5682 | Phase 3 |
0.8 | Intermediate Similarity | NPD5684 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD6417 | Clinical (unspecified phase) |
0.8 | Intermediate Similarity | NPD5683 | Clinical (unspecified phase) |
0.7958 | Intermediate Similarity | NPD194 | Clinical (unspecified phase) |
0.7904 | Intermediate Similarity | NPD2631 | Clinical (unspecified phase) |
0.7904 | Intermediate Similarity | NPD2632 | Approved |
0.7904 | Intermediate Similarity | NPD2630 | Approved |
0.7857 | Intermediate Similarity | NPD9633 | Phase 3 |
0.7829 | Intermediate Similarity | NPD536 | Clinical (unspecified phase) |
0.777 | Intermediate Similarity | NPD9408 | Phase 3 |
0.7718 | Intermediate Similarity | NPD7158 | Phase 1 |
0.7703 | Intermediate Similarity | NPD582 | Approved |
0.7582 | Intermediate Similarity | NPD3708 | Phase 2 |
0.7529 | Intermediate Similarity | NPD7138 | Phase 2 |
0.7468 | Intermediate Similarity | NPD4074 | Clinical (unspecified phase) |
0.7468 | Intermediate Similarity | NPD3085 | Phase 1 |
0.7419 | Intermediate Similarity | NPD3086 | Phase 3 |
0.7372 | Intermediate Similarity | NPD231 | Clinical (unspecified phase) |
0.7293 | Intermediate Similarity | NPD2965 | Clinical (unspecified phase) |
0.7266 | Intermediate Similarity | NPD9606 | Approved |
0.7261 | Intermediate Similarity | NPD9605 | Phase 3 |
0.7253 | Intermediate Similarity | NPD2876 | Phase 3 |
0.7253 | Intermediate Similarity | NPD2877 | Clinical (unspecified phase) |
0.7241 | Intermediate Similarity | NPD4054 | Clinical (unspecified phase) |
0.7219 | Intermediate Similarity | NPD3696 | Approved |
0.7219 | Intermediate Similarity | NPD3695 | Approved |
0.7214 | Intermediate Similarity | NPD9607 | Approved |
0.7174 | Intermediate Similarity | NPD2824 | Phase 2 |
0.7118 | Intermediate Similarity | NPD1046 | Clinical (unspecified phase) |
0.7047 | Intermediate Similarity | NPD209 | Clinical (unspecified phase) |
0.7032 | Intermediate Similarity | NPD171 | Discontinued |
0.7021 | Intermediate Similarity | NPD2903 | Clinical (unspecified phase) |
0.7021 | Intermediate Similarity | NPD2902 | Phase 2 |
0.698 | Remote Similarity | NPD545 | Clinical (unspecified phase) |
0.6929 | Remote Similarity | NPD9374 | Approved |
0.6915 | Remote Similarity | NPD4495 | Phase 1 |
0.6906 | Remote Similarity | NPD9373 | Approved |
0.6879 | Remote Similarity | NPD1730 | Discontinued |
0.6875 | Remote Similarity | NPD1063 | Phase 2 |
0.6875 | Remote Similarity | NPD353 | Discontinued |
0.6867 | Remote Similarity | NPD527 | Clinical (unspecified phase) |
0.6867 | Remote Similarity | NPD547 | Clinical (unspecified phase) |
0.6859 | Remote Similarity | NPD4240 | Approved |
0.6853 | Remote Similarity | NPD307 | Approved |
0.6849 | Remote Similarity | NPD9084 | Phase 2 |
0.68 | Remote Similarity | NPD282 | Approved |
0.6776 | Remote Similarity | NPD1119 | Phase 2 |
0.6687 | Remote Similarity | NPD775 | Approved |
0.6624 | Remote Similarity | NPD1430 | Approved |
0.6624 | Remote Similarity | NPD1431 | Approved |
0.6624 | Remote Similarity | NPD2253 | Discontinued |
0.6623 | Remote Similarity | NPD8829 | Clinical (unspecified phase) |
0.6615 | Remote Similarity | NPD5080 | Phase 2 |
0.6611 | Remote Similarity | NPD2152 | Clinical (unspecified phase) |
0.6601 | Remote Similarity | NPD1058 | Discontinued |
0.6601 | Remote Similarity | NPD9083 | Clinical (unspecified phase) |
0.6573 | Remote Similarity | NPD9584 | Phase 2 |
0.6564 | Remote Similarity | NPD5079 | Phase 2 |
0.6522 | Remote Similarity | NPD7531 | Clinical (unspecified phase) |
0.6522 | Remote Similarity | NPD8836 | Approved |
0.6519 | Remote Similarity | NPD207 | Discontinued |
0.649 | Remote Similarity | NPD1128 | Approved |
0.649 | Remote Similarity | NPD1127 | Approved |
0.6489 | Remote Similarity | NPD4458 | Phase 2 |
0.6489 | Remote Similarity | NPD4459 | Clinical (unspecified phase) |
0.6467 | Remote Similarity | NPD281 | Approved |
0.6463 | Remote Similarity | NPD9409 | Discontinued |
0.6433 | Remote Similarity | NPD799 | Phase 1 |
0.6433 | Remote Similarity | NPD1808 | Phase 1 |
0.6383 | Remote Similarity | NPD9417 | Phase 3 |
0.6383 | Remote Similarity | NPD9416 | Phase 3 |
0.6377 | Remote Similarity | NPD6840 | Approved |
0.6369 | Remote Similarity | NPD6112 | Approved |
0.6364 | Remote Similarity | NPD9375 | Discontinued |
0.6352 | Remote Similarity | NPD1118 | Discontinued |
0.6333 | Remote Similarity | NPD798 | Discontinued |
0.6306 | Remote Similarity | NPD1121 | Approved |
0.6306 | Remote Similarity | NPD535 | Approved |
0.6306 | Remote Similarity | NPD1120 | Approved |
0.6286 | Remote Similarity | NPD9626 | Clinical (unspecified phase) |
0.6242 | Remote Similarity | NPD9484 | Clinical (unspecified phase) |
0.6221 | Remote Similarity | NPD2593 | Clinical (unspecified phase) |
0.6209 | Remote Similarity | NPD515 | Phase 1 |
0.6198 | Remote Similarity | NPD5486 | Discontinued |
0.6197 | Remote Similarity | NPD1816 | Clinical (unspecified phase) |
0.6173 | Remote Similarity | NPD1117 | Clinical (unspecified phase) |
0.6159 | Remote Similarity | NPD8830 | Phase 3 |
0.6143 | Remote Similarity | NPD7502 | Clinical (unspecified phase) |
0.6122 | Remote Similarity | NPD9406 | Approved |
0.6105 | Remote Similarity | NPD691 | Discontinued |
0.6103 | Remote Similarity | NPD5458 | Discontinued |
0.6083 | Remote Similarity | NPD8250 | Phase 2 |
0.6078 | Remote Similarity | NPD78 | Approved |
0.6078 | Remote Similarity | NPD9544 | Approved |
0.6071 | Remote Similarity | NPD7842 | Phase 2 |
0.604 | Remote Similarity | NPD8831 | Approved |
0.604 | Remote Similarity | NPD8833 | Approved |
0.6014 | Remote Similarity | NPD757 | Phase 3 |
0.6 | Remote Similarity | NPD9360 | Approved |
0.599 | Remote Similarity | NPD796 | Phase 2 |
0.5933 | Remote Similarity | NPD1368 | Approved |
0.5903 | Remote Similarity | NPD9291 | Approved |
0.5902 | Remote Similarity | NPD534 | Phase 2 |
0.5902 | Remote Similarity | NPD537 | Phase 2 |
0.5897 | Remote Similarity | NPD1085 | Approved |
0.5897 | Remote Similarity | NPD1775 | Approved |
0.5896 | Remote Similarity | NPD5627 | Approved |
0.5894 | Remote Similarity | NPD237 | Clinical (unspecified phase) |
0.5882 | Remote Similarity | NPD2221 | Clinical (unspecified phase) |
0.5876 | Remote Similarity | NPD5665 | Clinical (unspecified phase) |
0.5852 | Remote Similarity | NPD5768 | Phase 2 |
0.5843 | Remote Similarity | NPD9704 | Approved |
0.5838 | Remote Similarity | NPD1017 | Clinical (unspecified phase) |
0.5833 | Remote Similarity | NPD3849 | Clinical (unspecified phase) |
0.5825 | Remote Similarity | NPD4555 | Clinical (unspecified phase) |
0.5798 | Remote Similarity | NPD3913 | Clinical (unspecified phase) |
0.5789 | Remote Similarity | NPD578 | Discontinued |
0.5769 | Remote Similarity | NPD6381 | Phase 2 |
0.5765 | Remote Similarity | NPD4599 | Clinical (unspecified phase) |
0.5764 | Remote Similarity | NPD8837 | Clinical (unspecified phase) |
0.5759 | Remote Similarity | NPD1356 | Approved |
0.5759 | Remote Similarity | NPD1354 | Approved |
0.5759 | Remote Similarity | NPD1355 | Clinical (unspecified phase) |
0.5752 | Remote Similarity | NPD580 | Discontinued |
0.5714 | Remote Similarity | NPD3697 | Discontinued |
0.5696 | Remote Similarity | NPD9366 | Approved |
0.5695 | Remote Similarity | NPD5171 | Clinical (unspecified phase) |
0.5691 | Remote Similarity | NPD9582 | Phase 3 |
0.569 | Remote Similarity | NPD6023 | Discontinued |
0.5683 | Remote Similarity | NPD4089 | Clinical (unspecified phase) |
0.5678 | Remote Similarity | NPD34 | Approved |
0.5678 | Remote Similarity | NPD4715 | Clinical (unspecified phase) |
0.5678 | Remote Similarity | NPD4713 | Clinical (unspecified phase) |
0.5678 | Remote Similarity | NPD4714 | Approved |
0.5676 | Remote Similarity | NPD613 | Phase 2 |
0.5671 | Remote Similarity | NPD9550 | Approved |
0.5671 | Remote Similarity | NPD9551 | Approved |
0.5669 | Remote Similarity | NPD579 | Clinical (unspecified phase) |
0.5667 | Remote Similarity | NPD9358 | Approved |
0.5667 | Remote Similarity | NPD9359 | Approved |
0.5646 | Remote Similarity | NPD245 | Suspended |
0.5632 | Remote Similarity | NPD2591 | Phase 2 |
0.5632 | Remote Similarity | NPD1731 | Clinical (unspecified phase) |
0.5632 | Remote Similarity | NPD5757 | Discontinued |
0.5625 | Remote Similarity | NPD5336 | Phase 1 |
0.5625 | Remote Similarity | NPD5337 | Phase 1 |
0.5622 | Remote Similarity | NPD7323 | Phase 2 |
0.5613 | Remote Similarity | NPD9290 | Approved |
0.5608 | Remote Similarity | NPD2457 | Phase 2 |
0.5608 | Remote Similarity | NPD2456 | Phase 2 |
0.56 | Remote Similarity | NPD2180 | Approved |
PubChem CID   | 21704 |
ChEMBL   | CHEMBL1090 |
ZINC   |
Molecular Weight:   | 267.10 |
ALogP:   | -2.2791 |
MLogP:   | 1.57 |
XLogP:   | -1.809 |
# Rotatable Bonds:   | 6 |
Polar Surface Area:   | 139.54 |
# H-Bond Aceptor:   | 9 |
# H-Bond Donor:   | 4 |
# Rings:   | 3 |
# Heavy Atoms:   | 19 |